Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of K-808 in PBC
NCT06525311Phase 1Completed
- Start
- Oct 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of pemafibrate in primary biliary cholangitis (PBC) (2 arms). Primary endpoints: Area under the curve from 0 to infinity, Area under the curve from time 0 to last quantifiable time and 14 more. Started Oct 2024; status: completed.
02
Drugs
pemafibrate
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT06525311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06525311.